SEOM clinical guideline of diagnosis and management of low-grade glioma (2017)

• J. M. Sepúlveda-Sánchez ^[3] ; J. Muñoz Langa ^[4] ; M. Á. Arráez ^[5] ; J. Fuster ^[1] ; A. Hernández Laín ^[3] ; G. Reynés ^[4] ; V. Rodríguez González ^[3] ; E. Vicente ^[6] ; M. Vidal Denis ^[5] ; Ó. Gallego ^[2]
  1. [1] Hospital Universitario Son Espases

     Hospital Universitario Son Espases

     Palma de Mallorca, España

     
  2. [2] Hospital de la Santa Creu i Sant Pau

     Hospital de la Santa Creu i Sant Pau

     Barcelona, España

     
  3. [3] Hospital Universitario Madrid, España
  4. [4] Hospital Universitari I Politècnic la Fe, España
  5. [5] HRU Carlos Haya, España
  6. [6] C.H.U. Insular-Materno Infantil de Gran Canaria, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 20, Nº. 1 (January 2018), 2018, págs. 3-15
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Diffuse infiltrating low-grade gliomas include oligodendrogliomas and astrocytomas, and account for about 5% of all primary brain tumors. Treatment strategies for these low-grade gliomas in adults have recently changed. The 2016 World Health Organization (WHO) classification has updated the definition of these tumors to include their molecular characterization, including the presence of isocitrate dehydrogenase (IDH) mutation and 1p/19p codeletion. In this new classification, the histologic subtype of grade II-mixed oligoastrocytoma has also been eliminated. The precise optimal management of patients with low-grade glioma after resection remains to be determined. The risk–benefit ratio of adjuvant treatment must be weighed for each individual.